Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Combined With Capecitabine and Bevacizumab for HER2-Positive Breast Cancer With Brain Metastases
NCT06152822Phase 2Unknown
- Sponsor
- Tongji Hospital
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer, sponsored by Tongji Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06152822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152822.